Legend Biotech Stock - Oppenheimer reiterates Buy rating

Oppenheimer has reaffirmed its positive stance on Legend Biotech stock with a reiterated Buy rating and a $75 price target. On this Wednesday, investor focus also turns to the company’s operational progress and partnership-driven strategy in cell therapy.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 14:03 CET. Details in the imprint.

Legend Biotech (US52490G1022) draws fresh analyst attention after Oppenheimer reiterated its Buy rating and confirmed a $75 price target on the stock, according to an update cited by The Globe and Mail on 06/17/2026. The call underscores ongoing confidence in the biotech’s cell therapy pipeline and partnerships.

Oppenheimer’s latest call

Oppenheimer analyst Kostas Biliouris maintained a Buy rating on Legend Biotech shares and set a $75 price target in a note dated 06/17/2026, as reported by The Globe and Mail’s market data section. This reiteration keeps Legend among the broker’s favored cell therapy names.

The renewed call follows a period of pronounced volatility in Legend Biotech shares, with recent commentary on platforms such as TipRanks pointing to profit-taking after a strong earlier run in the stock. Against this backdrop, Oppenheimer’s stance signals continued conviction in the long-term story.

Operations and strategy on Wednesday

Operationally, Legend Biotech continues to build its business around cell therapies for hematologic malignancies, led by its BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel) developed with Janssen, a Johnson & Johnson company. The partnership structure allows Legend to focus on research and manufacturing while leveraging its partner’s global commercial network.

Recent financial breakdowns show that Legend’s revenue is now largely driven by collaboration-derived milestones and commercial revenue linked to Carvykti, with total top-line contributions reflecting the product’s expanding geographic footprint. Management has emphasized reinvesting proceeds into pipeline development, including earlier-stage cell therapy candidates.

How the company makes money

Legend Biotech generates revenue mainly from its alliance with Janssen on Carvykti, including product sales-based revenue share, milestones and manufacturing supply agreements. Additional upside potential rests in advancing its broader pipeline of cell therapies targeting other blood cancers and solid tumors.

Where the stock trades today

Legend Biotech shares (US52490G1022) trade on the Nasdaq at $35.48 as of 06/17/2026, 20:00 ET in after-hours indications.

Key facts on Legend Biotech stock

• Company: Legend Biotech Corporation
• ISIN: US52490G1022
• WKN: A2P8ZL
• Ticker: LEGN
• Venue: Nasdaq
• Price (as of 06/17/2026, 20:00 ET): 35.48 USD
• Market cap: 6.20 billion USD (as of 06/17/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: not a member of the S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.